Hetty Waskin - Concepedia

Author

Hetty Waskin

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

H A Waskin, H Waskin, H. A. Waskin, H. Waskin, H.A. Waskin, HETTY WASKIN, Hetty A Waskin, Hetty A. Waskin, Hetty WASKIN, Hetty Waskin

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Duke Medical Center Duke University MSD (Netherlands)Juravinski Hospital

About

Hetty Waskin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug safety.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	19	1.9K
2	Health Sciences	3	3	528
3	Public Health	3	3	118
4	Social Sciences	1	1	41
5	Diagnostic Sciences	1	1	41

Hetty Waskin

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
A Controlled Trial of Trimethoprim–Sulfamethoxazole or Aerosolized Pentamidine for Secondary Prophylaxis of<i>Pneumocystis carinii</i>Pneumonia in Patients with the Acquired Immunodeficiency Syndrome William D. Hardy, Judith Feinberg, Dianne M. Finkelstein, New England Journal of Medicine	1992	344
A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection William G. Powderly, Dianne M. Finkelstein, Judith Feinberg, New England Journal of Medicine	1995	321
Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers Carlos A. Morillo, Hetty Waskin, Sergio Sosa‐Estáni, Journal of the American College of Cardiology Eliminating ParasitesParasitic DiseaseAntiparasitic AgentMedicineParasitic Protozoa	2017	309
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial Johan Maertens, Galia Rahav, Dong‐Gun Lee, The Lancet Invasive AspergillosisPosaconazole Versus VoriconazoleAntifungal AgentAntifungal AgentsMedicinal Fungi	2021	257
FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. John M. Hoffman, Hetty Waskin, T Schifter, PubMed Semiquantitative AnalysisPet-mriDiagnosisPathologyBrain Lesion	1993	256
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease Oliver A. Cornely, Rafael F. Duarte, Shariq Haider, Journal of Antimicrobial Chemotherapy	2015	167
Manifestations of Pulmonary Cryptococcusis in Patients with Acquired Immunodeficiency Syndrome Miriam L. Cameron, John Bartlett, Harry A. Gallis, Clinical Infectious Diseases	1990	163
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1 Miriam L. Cameron, Wiley A. Schell, Steve Bruch, Antimicrobial Agents and Chemotherapy Clinical SymptomsVitro SusceptibilityImmunologyClinical MycologyAntimicrobial Chemotherapy	1993	153
Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET) Alison E. Heald, John M. Hoffman, John Bartlett, International Journal of STD & AIDS Pet-mriDiagnosisPathologyBrain LesionPathologic Lesion	1996	119
Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia Rafael F. Duarte, Javier López‐Jiménez, Oliver A. Cornely, Antimicrobial Agents and Chemotherapy	2014	107

Page 1